CG
DARE icon

Cutler Group’s Dare Bioscience DARE Stock Holding History

Cutler Group’s Portfolio DARE Stock Details DARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-8
Closed -$2K – 6727
2016
Q1 		$2K Buy
+8
New +$2.26K ﹤0.01% 5530

Other funds holding DARE

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVMCI
Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Cutler Group's DARE Position: Q2 2016 in Review

Cutler Group sold out of Dare Bioscience (DARE) in Q2 2016, closing a stake of 8 shares — an estimated $2K sold.

Cutler Group first reported a position in DARE in Q1 2016 and held it in 1 quarter. The position peaked at $2K in Q1 2016. 34 funds tracked by Wall St. Rank hold DARE as of Q2 2016.

  • Cutler Group reported no remaining Dare Bioscience position as of Q2 2016 after selling out during the quarter.
  • Cutler Group sold 8 Dare Bioscience shares in Q2 2016, an estimated $2K.
  • Cutler Group first reported a position in Dare Bioscience in Q1 2016 and held it in 1 quarter.
  • Cutler Group's Dare Bioscience position peaked at $2K in Q1 2016.
  • 34 funds tracked by Wall St. Rank held Dare Bioscience as of Q2 2016.

Based on Cutler Group's 13F filing for Q2 2016, filed 12 Jul 2016.